Recently added

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts

Pronsati, Nancee; Green, Gerald; Liu, Geoffrey; Bauer, Todd; Goto, Yasushi; FELIP, ENRIQUETA (Elsevier, 2025-08)

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

Feijoo, Samantha; Vilaseca Jolonch, Andreu; Ariño, Helena; IACOBONI, GLORIA; Zabalza, Ana; Fissolo, Nicolás Miguel; AREVALO, MARIA JESUS; Cecilia del Carmen, Carpio Segura; Sanchez-Salinas, Mario Andrés; Tintore, Mar; Comabella Lopez, Manuel; Barba, Pere; Vidal-Jordana, Angela; Montalban, Xavier (Wiley, 2025-08)

The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients

Malhotra Sareen, Sunny; Castillo Justribo, Joaquin; La Puma, Delon ; Vilaseca Jolonch, Andreu; Urcelay, Elena; Castillo Juárez, Mireia; Aroca-Alsina, Montserrat; Vidal-Jordana, Angela; Pappolla, Agustin; Carvajal, René; Cobo-Calvo, Alvaro; Mongay-Ochoa, Neus; Rodriguez Acevedo, Breogan; TUR, CARMEN; Villacieros-Álvarez, Javier; Ariño, Helena; Zabalza, Ana; midaglia, luciana; Sastre Garriga, Jaume; Tintore, Mar; Rio, Jordi; Comabella Lopez, Manuel; Arrambide, Georgina; Montalban, Xavier (Wiley, 2025-07)

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

Cercek, Andrea; Starling, Naureen; Chen, Eric; Salvatore, Lisa; BACHET, Jean-Baptiste; Capdevila Castillon, Jaume (Elsevier, 2025-06)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

steuer, conor; Su, Wu-Chou; Nishio, Makoto; Hayashi, Hidetoshi; Johnson, Melissa; Kim, Dong-Wan; FELIP, ENRIQUETA (American Society of Clinical Oncology, 2025-09-01)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Institut Català de la Salut - ICS: Recent submissions

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Institut Català de la Salut - ICS: Recent submissions

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts ﻿

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy ﻿

The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients ﻿

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1) ﻿

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy ﻿

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy